Lonza Group AG operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Lonza Group AG with three other
pharmaceutical manufacturers in Europe:
H. Lundbeck A/S
sales of 17.67 billion Danish Kroner [US$2.77 billion]
of which 100%
Hikma Pharmaceuticals PLC
of UNITED KINGDOM
(£1.81 billion [US$2.50 billion]
of which 42%
was Injectable Pharmaceuticals), and
Stada Arzneimittel AG
based in GERMANY
(3.01 billion Euros [US$3.50 billion]
of which 55%
During the second
quarter of 2021, sales at Lonza Group AG totalled
2.54 billion Swiss Francs.
This is a drop of 17.3%
from the 3.07 billion Swiss Francs in sales at the company during the second quarter in 2020.
During the year ended December of 2020, sales at
Lonza Group AG were 4.51 billion Swiss Francs (US$4.91 billion).
decrease of 23.9%
versus 2019, when the company's sales were 5.92 billion Swiss Francs.
Contributing to the drop in overall sales was the 40.0% decline
in Eliminations, from 60.00 million Swiss Francs to 36.00 million Swiss Francs.
There were also decreases in sales in
Specialty Ingredients (down 0.9% to 1.68 billion Swiss Francs)
However, these declines were partially offset by the increase in sales of
Pharma&biotech (up 7.3% to 4.47 billion Swiss Francs)